MEDP - NASDAQ
Medpace Holdings, Inc.
$450.81
+1.2%Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
At a Glance
Live SnapshotMedpace Holdings, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Medpace Holdings, Inc. Cash Flow Statement
MEDP • NASDAQ
| Medpace Holdings, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
451.1M | 404.4M | 282.8M | 245.4M | 181.8M | 145.4M | 100.4M | 73.2M | 39.1M | 13.4M | -8.7M | -15.6M | 24.8M | |
27.2M | 29.3M | 26.3M | 22.3M | 21.1M | 19.5M | 23.2M | 38.8M | 46.5M | 58.1M | 69.5M | 68.1M | 30.5M | |
80.8M | -26.6M | -25.1M | -23M | -37.1M | 527K | 10.1M | 3.9M | 3.2M | -9M | -12.7M | 0.0 | 6M | |
34.8M | 25.5M | 20.5M | 21.4M | 14.5M | 13.8M | 20.7M | 6.5M | 4.5M | 9.8M | 22.3M | 12.8M | 2M | |
23.1M | 19.1M | 22.4M | 15.9M | 16.3M | 13.2M | 11.9M | -5.4M | -8.8M | 12.3M | 11.8M | 18.8M | 5.9M | |
(0.0) | (83.6M) | (76.4M) | (50.2M) | (56.2M) | (23.1M) | (13.2M) | (23.3M) | (17.2M) | (17.7M) | (10.6M) | (0.0) | (5.8M) | |
96.3M | 157.2M | 106.5M | 106.1M | 66.7M | 66.3M | 35.6M | 39.6M | 12.9M | 7.1M | 3.6M | -8.9M | 28.9M | |
713.2M | 608.8M | 433.4M | 388.1M | 263.3M | 258.7M | 201.9M | 156.6M | 97.4M | 91.7M | 85.9M | 75.2M | 98.1M | |
INVESTING ACTIVITIES | |||||||||||||
(0.0) | -36.5M | -36.6M | -36.9M | -28.3M | -31.3M | -17.9M | -16M | -11.7M | -13.5M | -6.5M | -5.3M | -4.6M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -901.8M | (0.0) | |
-31.1M | 8.2M | 2M | -1.9M | -3.1M | 126K | -1.2M | -949K | -513K | 115K | 33K | 301K | 89K | |
-31.1M | -28.3M | -34.6M | -38.7M | -31.4M | -31.2M | -19.1M | -17M | -12.2M | -13.4M | -6.4M | -908.5M | -4.5M | |
FINANCING ACTIVITIES | |||||||||||||
-860.4M | -169.9M | -144M | -847.8M | -62.1M | -98.3M | 0.0 | 0.0 | -155.6M | 173.6M | 608K | 414M | 1.2M | |
0.0 | 0.0 | -50M | 50M | 0.0 | 0.0 | -80.4M | -142.2M | 57.6M | -226.1M | -116.1M | 462.1M | -96.4M | |
-917.4M | -169.9M | -144M | -847.8M | -62.1M | -98.3M | (0.0) | (0.0) | -155.6M | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 15.9M | 11.4M | 22.1M | 17.6M | 16M | 6.5M | 608K | 130K | -5.5M | -1M | 6.1M | -597K | |
-860.4M | -154M | -182.6M | -775.8M | -44.5M | -82.3M | -73.9M | -141.6M | -97.8M | -58M | -116.5M | 882.2M | -95.9M | |
CASH FLOW SUMMARY | |||||||||||||
5.9M | -2.5M | 1.1M | -6.6M | -4M | 666K | -167K | -1.2M | 1.8M | -632K | -601K | 6.5M | 159K | |
-172.4M | 424M | 217.2M | -433M | 183.5M | 145.8M | 108.6M | -3.2M | -10.9M | 19.7M | -37.7M | 55.4M | -2M | |
669.4M | 245.4M | 28.3M | 461.3M | 277.8M | 131.9M | 23.3M | 26.5M | 37.4M | 17.7M | 55.4M | 0.0 | 25.9M | |
497M | 669.4M | 245.4M | 28.3M | 461.3M | 277.8M | 131.9M | 23.3M | 26.5M | 37.4M | 17.7M | 55.4M | 23.9M | |
681.9M | 572.3M | 396.7M | 351.2M | 235.1M | 227.3M | 184M | 140.6M | 85.1M | 78.2M | 79.4M | 69.9M | 93.6M |
SEC Filings
MEDP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 19, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 23, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 22, 2026 | April 21, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 15, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 09, 2026 | February 09, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | October 23, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 22, 2025 | October 22, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | July 22, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 21, 2025 | July 17, 2025 | 2025 |
Related Guides
Continue your MEDP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.